ABSTRACT
More than 4 fibroadenomas in a single breast are uncommon. Repeated recurrences of supernumerary fibroadenomas, in multiple numbers, after excision, are extremely rare. The malignant potential of breast fibroadenoma increases significantly in women with complex fibroadenomas, proliferative disease or a family history of breast cancer. Such a condition poses a management dilemma to the surgeon. Prophylactic bilateral mastectomy is controversial, and requires a rigorous assessment of risk benefit ratio and a better assessment of psychosocial impact and ethical issues. More often than not, the patient prefers repeat excision and close surveillance as the most agreeable course of action; the relatively higher risk of malignancy notwithstanding. Repeated excision as new fibroadenomas appear seems to be a feasible option.
ABSTRACT
Background: Lipid abnormalities are common among patients with chronic kidney disease (CKD) and it tends to persist/worsen even after initiating treatment. The cardiovascular mortality and morbidity remains significantly high in this population. The present study was carried out to assess the effect of yoga therapy on fasting lipid profile in CKD patients.Methods: It was an interventional case control study on CKD patients with and without yoga in a tertiary care hospital. About 60 CKD patients aged >18 years were enrolled for the study and were divided into 2 groups of 30 each. Subjects in Group 1 who underwent yoga therapy. Group 2 subjects did not do yoga and they served as controls. Serum lipid profile, RFT and BP were estimated for all patients. Chi-square test, Paired and unpaired t test, mean and delta change were used for comparison. A p-value of <0.05 was considered statistically significant.Results: Out of 60 patients, males were predominant. There was significant reduction in Triglycerides, LDL and VLDL in the yoga group. Total cholesterol also reduced but was not statistically significant. HDL also increased but insignificant statistically.Conclusions: Yoga therapy can be a new added adjuvant and cost effective to the standard lipid lowering agent to reduce the lipid levels in CKD patients.